

### Amendments to the Claims

1. (currently amended) A spontaneously dispersible pharmaceutical composition for oral administration comprising
  - 1) N-benzoyl-staurosporine,
  - 2) a hydrophilic component, and
  - 23) a surfactant,wherein the hydrophilic component is selected from the group of ethanol, 1,2-propylene glycol, and a polyethylene glycol, and  
wherein the surfactant is selected from the group of polyoxyethylenes, polyglycerols and related polyols, polyalkylene oxide copolymers, polyoxyethylene castor oil, a polyoxyethylene alkyl ether, and a polysorbate,  
wherein the spontaneously dispersible pharmaceutical composition produces colloidal structures when diluted in an aqueous medium.
2. (previously presented) A composition as claimed in claim 1 further comprising a lipophilic component.
3. ~~(cancelled) A composition according to claim 1 wherein the hydrophilic component comprises ethanol, 1,2-propylene glycol or a polyethylene glycol.~~
4. (previously presented) A composition according to claim 1 wherein the surfactant is selected from the group consisting of polyoxyethylenes, polyglycerols and related polyols, and polyalkylene oxide copolymers.
5. (previously presented) A composition according to claim 1 wherein the surfactant is selected from the group consisting of a polyoxyethylene castor oil, a polyoxyethylene alkyl ether, and a polysorbate.
6. (previously presented) A composition according to claim 1 wherein the surfactant has an HLB value of greater than 10 and the composition further comprises a co-surfactant having an HLB value of less than 10.
7. (previously presented) A composition as claimed in claim 6 wherein the surfactant is selected from the group consisting of a polyoxyethylene castor oil, a polyoxyethylene alkyl ether, and a polysorbate, and the co-surfactant comprises a transesterified ethoxylated vegetable oil.

8. (previously presented) A composition as claimed in claim 2 wherein the surfactant has an HLB value of greater than 10 and the lipophilic component comprises a fatty acid glyceride.
9. (previously presented) A spontaneously dispersible pharmaceutical composition for oral administration comprising
  - (a) up to 20% by weight of N-benzoyl-staurosporine,
  - (b) 5 to 50% by weight of a hydrophilic component,
  - (c) 5 to 810% of a surfactant or surfactant mixture,
  - (d) 5 to 85% of a lipophilic component, and
  - (e) 0.05 to 5% of an additive.
10. (withdrawn) A method of treatment for treating subjects in need of N-benzoyl-staurosporine therapy comprising administering a dispersible pharmaceutical composition according to claim 1 to a subject in need of such treatment.
11. (previously presented) A pharmaceutical composition for oral administration comprising N-benzoylstaurosporine and having
  - (a) a variability of bioavailability levels of N-benzoylstaurosporine of from 5 to 17%;
  - (b) an AUC (0-48h)/dose value (in (h·nmol/L)/(mg/kg)) of from 380 to 2000, or
  - (c) a  $C_{max}$  dose value (in (nmol/L)/(mg/kg)) of from 60 to 310, upon administration of a dose (in mg/kg) of N-benzoylstaurosporine.
12. (withdrawn) A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine by mixing N-benzoylstaurosporine with a carrier comprising a hydrophilic component, and a surfactant.
13. (withdrawn) A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine, said method comprising orally administering a composition according to claim 1 to fasted beagle dogs.